NUT Midline Carcinoma: A Rare Solid Tumour Characterized by Chromosome Rearrangement

作者全名："Zhang, Huan; Kong, Weili; Liang, Wei"

作者地址："[Zhang, Huan; Liang, Wei] Chongqing Med Univ, Dept Oncol, Affiliated Hosp 3, Chongqing 401120, Peoples R China; [Kong, Weili] Sichuan Univ, West China Hosp, Dept Otorhinolaryngol Head & Neck Surg, Chengdu 610041, Sichuan, Peoples R China"

通信作者："Liang, W (通讯作者)，Chongqing Med Univ, Dept Oncol, Affiliated Hosp 3, Chongqing 401120, Peoples R China."

来源：EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000831013900013

JCR分区：Q3

影响因子：2.65

年份：2022

卷号：2022

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：　

摘要："Objective. Rare and poorly differentiated NUT midline carcinoma (NMC) is a highly malignant tumour. However, due to the rarity of NMC, reports on its clinical, imaging, and pathologic features are still scarce. Methods. In this study, three patients diagnosed with NMC located in the parotid gland, lung, and trachea were used as examples to summarize the clinicopathological features of NMC. All the cases were diagnosed by measuring positive nuclear reactivity to NUT antibody after dual-colour FISH tests were conducted, and all of the results were positive, indicating chromosomal rearrangements on 15q14 of the NUT gene. Results. These three patients were treated with conventional treatments, including surgical therapy and chemoradiotherapy. Given the poor efficacy of intensive conventional treatment, two novel therapies, histone deacetylase inhibitors (HDACi) and bromodomain inhibitors (BETi) are recommended, as both can arrest the growth of tumour cells, and these targeted therapies may extend patient survival time in the future. Conclusions. NMC is an easily misdiagnosed cancer with a poor prognosis; therefore, improving the awareness of clinicians is critical for increasing the diagnostic accuracy, and selecting effective treatment is the main method to improve prognosis."

基金机构：　

基金资助正文：